What is Kypha?
Kypha operates as an immune insights company, specializing in advanced biomarker testing tailored for clinical laboratories, healthcare providers, and patients. The company's proprietary systems are designed to deliver precise, real-time information concerning complement and other proteins. This capability is crucial for enabling faster and more accurate treatment decisions in the management of immune-related conditions. Kypha offers a comprehensive suite of services, including assay development, custom panel creation, and exploratory biomarker analysis, all conducted under stringent regulatory compliance. Their technology facilitates simultaneous multiplex analysis alongside single analyte measurement, thereby enhancing both therapeutic development and the delivery of clinical care.
How much funding has Kypha raised?
Kypha has raised a total of $6.9M across 3 funding rounds:
Private Equity
$750K
Debt
$2.1M
Series A
$4M
Private Equity (2013): $750K, investors not publicly disclosed
Debt (2015): $2.1M, investors not publicly disclosed
Series A (2018): $4M, investors not publicly disclosed
What's next for Kypha?
The recent major strategic investment positions Kypha for accelerated growth and further development of its advanced biomarker testing platforms. With a clear focus on providing critical immune insights, the company is poised to expand its reach within the healthcare ecosystem. Future endeavors will likely involve scaling operations, enhancing technological capabilities, and forging deeper partnerships with healthcare providers and research institutions to leverage their data-driven insights for improved patient outcomes. The enterprise-level capital infusion suggests a strategic push towards market leadership and broader adoption of their diagnostic solutions.
See full Kypha company page
